Tesaro | pharmaphorum

Skip to main content

Friday 5 December 2025

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Tesaro

News

Roche Rituxan approval

Tesaro and Roche to combine drugs in bladder cancer trials

Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer.

News

AstraZeneca Amenities Building - Mississauga - Sept 2005
Non exclusive, unlimited time license for print & web to WZMH Architects

AZ's Lynparza becomes first PARP drug approved in breast can...

Lynparza first in class approved in breast cancer

News

clovis-oncology

Clovis PARP drug gets fast US review in new ovarian cancer u...

Impressed by survival data, FDA hastens review in expanded patient group

News

astrazeneca-sign

Tesaro gets European approval on Zejula, set to challenge AZ

Tesaro's PARP drug approved in wider ovarian cancer population

News

AstraZeneca (AZ)

Tesaro's Zejula primed for EU approval, battle with AZ

EU regulators recommend PARP inhibitor Zejula

News

trump_kentucky

Trump tax reform uncertainty puts biotech M&A on hold

Tesaro and Puma are potential takeover targets

Load more results

Editor's Picks

Latest Medicare pricing cuts promise $12bn in savings

NICE backs NHS use of Autolus' leukaemia CAR-T

£800m life sciences cluster opens in London

Sanofi's Paris HQ raided in tax fraud probe

Wearable alert system for epileptics set for European launch

News

NHS staff 'feel unprepared for digital transformation'

NHS staff 'feel unprepared for digital transformation'

A survey of NHS workers has found that almost two-thirds feel they are unprepared for the digital transformation objectives of the 10-Year Plan.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company